Lazar David E. 4
4 · Quantum Cyber N.V. · Filed Apr 28, 2026
Research Summary
AI-generated summary of this filing
Quantum Cyber (MYNZ) CEO David Lazar Receives 2M Preferred Shares
What Happened
David Lazar, CEO of Quantum Cyber N.V. (MYNZ), acquired two grants/awards on 2026-04-22: 1,000,000 Series D preferred shares and 1,000,000 Series E preferred shares at $1.50 per share (derivative securities). Each grant cost $1.5M for a combined cash consideration of $3.0M. These are additional to an earlier reported Feb 13, 2026 acquisition of 3,000,000 preferred shares (Series A–C) at $1.00 each.
Key Details
- Transaction date: April 22, 2026; Filing date: April 28, 2026 (filed after the typical 2-business-day Form 4 window).
- Securities acquired: 1,000,000 Series D preferred @ $1.50 ($1.5M) and 1,000,000 Series E preferred @ $1.50 ($1.5M). Total consideration for this filing: $3.0M.
- Holdings after transactions (preferred shares): total preferred reported = 5,000,000 (Series A–E: 3,000,000 from Feb 13 + 2,000,000 from Apr 22). The reporting person beneficially owns no ordinary (common) shares (Footnote F1).
- Conversion rights: Preferred shares are convertible at Lazar’s option for no additional consideration (Footnote F4). Per shareholder approval on April 22, 2026, each First Closing preferred (Series A–C) converts into 9 ordinary shares and each Second Closing preferred (Series D–E) converts into 225 ordinary shares (Footnote F3). That implies potential conversion into up to 477,000,000 ordinary shares (27,000,000 from Series A–C + 450,000,000 from Series D–E) if all preferred were converted.
- Other notes: Shareholders approved an increase in authorized ordinary shares (to at least 900,000,000), conversion mechanics, a reverse split, and board elections on April 22 (Footnote F3). Each preferred class is perpetual (no expiration) (Footnote F5).
Context
This filing records the acquisition of convertible preferred stock (derivative instruments), not immediate purchases of ordinary shares. Conversion is optional and would create a large number of common shares if exercised. The Apr 28 filing date is later than the usual 2-business-day Form 4 deadline, which may be noteworthy for investors tracking insider reporting timeliness. As always, this is a factual record of ownership changes and conversion rights, not a statement of intent or market prediction.
Insider Transaction Report
- Award
Series D Preferred Shares
[F2][F3][F4][F5]2026-04-22$1.50/sh+1,000,000$1,500,000→ 1,000,000 totalFrom: 2026-04-22→ Ordinary Shares (225,000,000 underlying) - Award
Series E Preferred Shares
[F2][F3][F4][F5]2026-04-22$1.50/sh+1,000,000$1,500,000→ 1,000,000 totalFrom: 2026-04-22→ Ordinary Shares (225,000,000 underlying)
- 0
Ordinary Shares
[F1]
Footnotes (5)
- [F1]No ordinary shares are beneficially owned.
- [F2]As previously reported, on February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Following Stockholder Approval (as defined below) which was obtained on April 22, 2026, the Reporting Person subsequently acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000.
- [F3]On April 22, 2026, the Company's shareholdes approved (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). Following the receipt of Stockholder Approval, each of the First Closing Shares are now convertible into 9 ordinary shares and each of the Second Closing Shares are now convertible into 225 ordinary shares.
- [F4]The Preferred Stock are convertible into ordinary shares at the option of the Reporting Person for no additional consideration.
- [F5]Each class of Preferred Stock is perpetual and therefore has no expiration date.